You are here

Diabetes Drug Albiglutide Submitted for FDA Review

Treatment replenishes GI peptide involved in insulin release (Jan. 14)

Albiglutide (GlaxoSmithKline) — an investigational once-weekly treatment for adults with type 2 diabetes — has been submitted to the FDA for review.

Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal, which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent.

Albiglutide consists of two copies of modified human GLP-1 fused in series to human albumin and is designed to have a longer duration of action than endogenous GLP-1.

Last year, positive results were reported from the Harmony 8 phase III trial, in which albiglutide was compared with a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin (Januvia, Merck Sharpe & Dohme), in 507 patients with type 2 diabetes and renal impairment.

At the 26-week primary endpoint, albiglutide showed clinically and statistically significant reductions in hemoglobin A1c from baseline (8.08% for albiglutide vs. 8.22% for sitagliptin) and superiority versus sitagliptin (reduction of –0.83% vs. –0.52%, respectively; P P = 0.0003 for superiority). At the primary endpoint, weight loss was significantly greater in the albiglutide group than in the sitagliptin group (–0.79 kg vs. –0.19 kg, respectively; P = 0.0281).

Sources: GSK; January 14, 2013; and GSK; July 11, 2012.

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status